Network-based identification genetic effect of SARS-CoV-2 infections to Idiopathic pulmonary fibrosis (IPF) patients

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is accountable for the cause of coronavirus disease (COVID-19) that causes a major threat to humanity. As the spread of the virus is probably getting out of control on every day, the epidemic is now crossing the most dreadful phase. Idiopathic pulmonary fibrosis (IPF) is a risk factor for COVID-19 as patients with long-term lung injuries are more likely to suffer in the severity of the infection. Transcriptomic analyses of SARS-CoV-2 infection and IPF patients in lung epithelium cell datasets were selected to identify the synergistic effect of SARS-CoV-2 to IPF patients. Common genes were identified to find shared pathways and drug targets for IPF patients with COVID-19 infections. Using several enterprising Bioinformatics tools, protein–protein interactions (PPIs) network was designed. Hub genes and essential modules were detected based on the PPIs network. TF-genes and miRNA interaction with common differentially expressed genes and the activity of TFs are also identified. Functional analysis was performed using gene ontology terms and Kyoto Encyclopedia of Genes and Genomes pathway and found some shared associations that may cause the increased mortality of IPF patients for the SARS-CoV-2 infections. Drug molecules for the IPF were also suggested for the SARS-CoV-2 infections.

Pulmonary long-term consequences of COVID-19 infections after hospital discharge

“…Although PAI levels are significantly elevated in the plasma of hospitalised COVID-19 patients [ 32 ] and mRNA levels are higher in the lungs of COVID-19 patients than in those of uninfected or influenza patients [ 33 ], we did not find differences, perhaps because we analysed a non-acute phase. Finally, ICAM, which is also elevated in the sera of patients with pulmonary fibrosis [ 34 ], in the context of the first transcriptomic analysis performed to date on SARS-CoV-2 and IPF, showed that it has a relevant role in both processes [ 35 ]. In our study, we found no significant differences.…”

Bioinformatics and system biology approach to identify the influences of COVID-19 on cardiovascular and hypertensive comorbidities

“…As of December \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{upgreek} \usepackage{mathrsfs} \setlength{\oddsidemargin}{-69pt} \begin{document} }{}$2020$\end{document} , almost \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{upgreek} \usepackage{mathrsfs} \setlength{\oddsidemargin}{-69pt} \begin{document} }{}$300$\end{document} countries and territories around the world have reported more than \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{upgreek} \usepackage{mathrsfs} \setlength{\oddsidemargin}{-69pt} \begin{document} }{}$65$\end{document} million confirmed cases resulting in over one and a half million deaths [ 1 , 2 , 6 ] Recent studies have found that some pre-existing conditions greatly increase the risk of severe symptoms and mortality in COVID- \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{upgreek} \usepackage{mathrsfs} \setlength{\oddsidemargin}{-69pt} \begin{document} }{}$19$\end{document} patients. These include pulmonary diseases, cardiovascular diseases, kidney disease, type 2 diabetes and hypertension [ 47 , 56 ]. Sequential Organ Failure Assessment (SOFA) scores have been reported significantly greater in SARS-CoV-2 associated deaths [ 49 , 69 ].…”

Protective Effect of Arbidol Against Pulmonary Fibrosis and Sepsis in Mice

“…It was found that the formation of fibrous streaks during rehabilitation ( Xu et al, 2020 ). A meta-analysis found that viral infections increase the risk of idiopathic pulmonary fibrosis, and COVID-19 patients in the recovery period may cause additional complications due to PF ( Sheng et al, 2020 ; Taz et al, 2020 ). Therefore, pulmonary fibrosis is likely to be one of the major complications in COVID-19 patients.…”